Stay updated on Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.7%
    Check dated 2025-06-19T19:17:53.000Z thumbnail image
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:05:33.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    1%
    Check dated 2025-05-29T05:49:35.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T13:46:23.000Z thumbnail image
  7. Check
    77 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the removal of detailed information about a phase II trial involving pembrolizumab for glioblastoma, while adding new identifiers and procedural details related to glioblastoma treatment, including radiation therapy and the drug temozolomide.
    Difference
    46%
    Check dated 2025-04-16T01:41:21.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new phase II study of Pembrolizumab in treating glioblastoma, with revised dates and definitions for key study metrics, including overall survival and disease progression assessments.
    Difference
    10%
    Check dated 2025-04-08T20:14:20.000Z thumbnail image

Stay in the know with updates to Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Standard Therapy in Glioblastoma Clinical Trial page.